Goldman Ismail Secures String of Dismissals on Preemption Grounds in SynchroMed Litigation

During the first quarter of 2017, three federal courts granted motions to dismiss product liability claims involving Medtronic’s SynchroMed® II Programmable Drug Infusion System, an implantable Class III medical device. Following the Goldman Ismail team’s briefing and oral argument, the courts all arrived at the conclusion that the plaintiffs’ pled claims were preempted by federal law. Joe Tomaselli, Tarek Ismail, and Rami Fakhouri represented Medtronic in these cases, the latest victories in the firm’s role as nationwide counsel in the SynchroMed litigation. Press coverage of the trio of preemption decisions is available here and here.